【摘要】 目的 对比环硅酸锆钠和聚苯乙烯磺酸钙治疗慢性肾脏病(chronic kidney disease,CKD)患者高钾血症的疗效和安全性。方法 回顾性选取2022年1月至2023年11月清远市人民医院收治的CKD高钾血症住院患者为研究对象，根据患者用药的不同分为环硅酸锆钠组和聚苯乙烯磺酸钙组。对两组患者进行1∶1倾向性评分匹配，最终43对数据成功匹配，比较匹配后的两组患者的疗效和不良反应发生率。结果 用药后，两组患者的血钾水平均显著低于本组用药前(P<0.05)，但两组患者的血钾水平比较差异无统计学意义(P>0.05)。两组患者的总有效率比较差异无统计学意义(χ~2=1.242,P=0.537)。用药后，环硅酸锆钠组患者的血钠水平显著高于用药前(P<0.05)，血钙水平用药前后比较差异无统计学意义(P>0.05)；聚苯乙烯磺酸钙组患者的血钠、血钙水平用药前后比较差异均无统计学意义(P>0.05)。两组各有1例患者出现低钾血症，均未见恶心、水肿、便秘、腹胀、腹泻等治疗相关不良反应，无实验室检查结果异常。结论 环硅酸锆钠与聚苯乙烯磺酸钙治疗CKD患者高钾血症的临床疗效相当，安全性良好。更多还原

【Abstract】 Objective To compare the efficacy and safety of sodium zirconium cyclosilicate and calcium polystyrene sulphonate in the treatment of hyperkalemia in chronic kidney disease(CKD). Methods Hospitalized patients with CKD hyperkalemia admitted to Qingyuan People’s Hospital from January 2022 to November 2023 were retrospectively selected as study objects,and were divided into sodium zirconium cyclosilicate group and calcium polystyrene sulphonate group according to different drug use. The two groups of patients were matched with 1:1 propensity score, and finally 43 pairs of data were successfully matched. The efficacy and incidence of adverse reactions were compared between two groups of patients after matching.Results After treatment, the serum potassium level in both groups was significantly lower than that before treatment(P<0.05),but there was no significant difference in serum potassium level between two groups(P>0.05). There was no significant difference in the total effective rate between two groups(χ~2=1.242, P=0.537). After treatment, the blood sodium level in sodium zirconium cyclosilicate group was significantly higher than that before treatment(P<0.05), there was no significant difference in blood calcium level before and after treatment(P>0.05). There was no significant difference in serum sodium and serum calcium before and after treatment in calcium polystyrene sulphonate group(P>0.05). There was one patient with hypokalemia in each group, and no treatment related adverse reactions such as nausea, edema, constipation, abdominal bloating and diarrhea were observed, and no abnormal laboratory test results were found. Conclusion The clinical efficacy of sodium zirconium cyclosilicate and calcium polystyrene sulphonate in treatment of hyperkalemia in CKD patients is comparable, and the safety is good.更多还原